<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
    xmlns:admin="http://webns.net/mvcb/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:content="http://purl.org/rss/1.0/modules/content/">

    <channel>
    
    <title>Amgen News Service: Pipeline News
</title>
    <link>http://www.amgennews.com/index.php</link>
    <description></description>
    <dc:language>en</dc:language>
    <dc:creator>piroc@piroc.com</dc:creator>
    <dc:rights>Copyright 2008</dc:rights>
    <dc:date>2008-06-18T15:06:00+00:00</dc:date>
    <admin:generatorAgent rdf:resource="http://expressionengine.com/" />
    

    <item>
      <title>Romiplostim Data Show Potential Long&#45;Term Efficacy and Safety in Adults with Chronic ITP</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/romiplostim_data_show_potential_long_term_efficacy_and_safety_in_adults_wit/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/romiplostim_data_show_potential_long_term_efficacy_and_safety_in_adults_wit/#When:05:45:00Z</guid>
      <description>COPENHAGEN, Denmark &amp;ndash; June 15, 2008 &amp;ndash; Amgen Inc. (NASDAQ: AMGN) today announced updated results from the ongoing, open&#45;label extension study on the long&#45;term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in the blood. The updated results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue ITP medications.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-06-15T05:45:00+00:00</dc:date>
    </item>

    <item>
      <title>Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/updated_data_from_ongoing_phase_3_trials/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/updated_data_from_ongoing_phase_3_trials/#When:06:44:01Z</guid>
      <description>CHICAGO &amp;ndash; June 1, 2008 &amp;ndash; Amgen (NASDAQ:AMGN) today announced updated interim pooled, blinded, safety results from two Phase 3 trials evaluating Vectibix(R) (panitumumab) in combination with standard chemotherapy in earlier lines of metastatic colorectal cancer (mCRC). Updated data from these trials, as well as the first prospective trial evaluating the impact of the clinical biomarker KRAS on Vectibix efficacy in combination with chemotherapy, were presented at the 2008 American Society of Clinical Oncology&#8217;s (ASCO) Annual Meeting in Chicago.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-06-01T06:44:01+00:00</dc:date>
    </item>

    <item>
      <title>Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_presents_new_data_at_asco_on_four_investigational_molecules_from_onco/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_presents_new_data_at_asco_on_four_investigational_molecules_from_onco/#When:17:15:01Z</guid>
      <description>CHICAGO &amp;ndash; May 31, 2008 &amp;ndash; Amgen (NASDAQ:AMGN) today announced interim results from four of the company&#8217;s investigational cancer agents. Data presented from trials with recombinant human (rh) Apo2L/TRAIL, AMG 479, AMG 102 and motesanib alone, and in combination with chemotherapy or other targeted agents, are a part of the robust oncology therapeutic development program organized in the pathway areas of apoptosis, growth regulation and angiogenesis. These studies were presented at the 2008 American Society of Clinical Oncology&#8217;s (ASCO) Annual Meeting in Chicago.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-05-31T17:15:01+00:00</dc:date>
    </item>

    <item>
      <title>Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_reports_positive_data_at_asco_from_three_studies_of_denosumab_in_canc/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_reports_positive_data_at_asco_from_three_studies_of_denosumab_in_canc/#When:17:04:00Z</guid>
      <description>CHICAGO &amp;ndash; May 31, 2008 &amp;ndash; Amgen (NASDAQ: AMGN) today announced results from three denosumab studies in cancer patients. A Phase 2 study of metastatic patients previously treated with IV bisphosphonates found that denosumab normalized a key marker of bone resorption at a significantly greater rate than that seen with continuation of IV bisphosphonates, and also patients receiving denosumab experienced fewer skeletal&#45;related events (SREs). A separate retrospective analysis comparing the results of this study to another Phase 2 study of patients never treated with an IV bisphosphonate revealed that the effect of denosumab on bone turnover markers was similar regardless of previous exposure to bisphosphonates. In addition, a sub&#45;analysis of a Phase 3 trial in an earlier&#45;stage cancer population of non&#45;metastatic breast cancer patients showed that denosumab increased bone mineral density (BMD) at all sites measured, including cortical bone. These results were presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-05-31T17:04:00+00:00</dc:date>
    </item>

    <item>
      <title>Interim Phase 2 Results of Open&#45;Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/interim_phase_2_results_of_open_label_clinical_trial_of_denosumab/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/interim_phase_2_results_of_open_label_clinical_trial_of_denosumab/#When:16:58:00Z</guid>
      <description>CHICAGO &amp;ndash; May 31, 2008 &amp;ndash; Amgen (NASDAQ:AMGN) today announced interim results of an open&#45;label Phase 2 study demonstrating a positive response rate to administration of denosumab in subjects with recurrent or unresectable giant cell tumor of bone. The study was presented at the 2008 American Society of Clinical Oncology (ASCO) annual meeting.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-05-31T16:58:00+00:00</dc:date>
    </item>

    <item>
      <title>Denosumab Achieved Superior Bone Mineral Density Gains in Head&#45;to&#45;Head Trial Versus Weekly Alendronate (FOSAMAX(R))</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/denosumab_achieved_superior_bone_mineral_density_gains_vs_fosamax/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/denosumab_achieved_superior_bone_mineral_density_gains_vs_fosamax/#When:05:18:00Z</guid>
      <description>BARCELONA, Spain &amp;ndash; May 28, 2008 &amp;ndash; Amgen (NASDAQ: AMGN) today announced complete results from a head&#45;to&#45;head, double&#45;blind study comparing the effects of twice&#45;yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate (FOSAMAX(R)) on bone mineral density (BMD) in postmenopausal women with low BMD. The results were presented during a late breaking session at this year&#8217;s 35th Annual European Symposium on Calcified Tissues (ECTS) meeting. Top&#45;line results of this study were previously reported in January 2008.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-05-28T05:18:00+00:00</dc:date>
    </item>

    <item>
      <title>Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/denosumab_osteoporosis_study_meets_primary_and_all_secondary_bone_mineral_d/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/denosumab_osteoporosis_study_meets_primary_and_all_secondary_bone_mineral_d/#When:13:49:00Z</guid>
      <description>Patients Transitioned from Alendronate to Denosumab Therapy Achieved Superior Gains in Bone Mineral Density Versus Those Continuing on Alendronate Therapy
THOUSAND OAKS, Calif. &amp;ndash; May 19, 2008 &amp;ndash; Amgen (NASDAQ: AMGN) today announced findings from a head&#45;to&#45;head, double&#45;blind trial comparing the effects of denosumab in post&#45;menopausal women with low bone mass transitioned from weekly alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone mineral density (BMD). The study demonstrated superior results for the primary and all secondary endpoints.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-05-19T13:49:00+00:00</dc:date>
    </item>

    <item>
      <title>Amgen Highlights Data to Be Presented at ASCO</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_highlights_data_to_be_presented_at_asco/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_highlights_data_to_be_presented_at_asco/#When:17:24:00Z</guid>
      <description>THOUSAND OAKS, Calif. &amp;ndash; May 15, 2008 &amp;ndash; Amgen (NASDAQ:AMGN) today announced it will present new data from the Company&#8217;s oncology portfolio on both approved and investigational cancer therapies at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting that will be held in Chicago from May 30 to June 3, 2008.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-05-15T17:24:00+00:00</dc:date>
    </item>

    <item>
      <title>Amgen Presents Preclinical and Clinical Data from Oncology Programs</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/amgen_presents_preclinical_and_clinical_data_from_oncology_programs/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/amgen_presents_preclinical_and_clinical_data_from_oncology_programs/#When:05:00:00Z</guid>
      <description>SAN DIEGO &amp;ndash; April 15, 2008 &amp;ndash; Amgen (NASDAQ:AMGN) today announced data generated by the company&#8217;s robust oncology research and development programs in the areas of apoptosis (programmed cell death) and cell growth regulation. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego were from five preclinical studies evaluating anti&#45;tumor activity, pharmacodynamics, and potential pre&#45;clinical and clinical biomarkers for investigational molecules AMG 655, AMG 479 and AMG 102.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-04-15T05:00:00+00:00</dc:date>
    </item>

    <item>
      <title>Early Data on Amgen&apos;s Anti&#45;Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types</title>
      <link>http://www.amgennews.com/index.php/2008NewsService/early_data_on_amgens_anti_angiogenesis_pipeline/</link>
      <guid>http://www.amgennews.com/index.php/2008NewsService/early_data_on_amgens_anti_angiogenesis_pipeline/#When:18:29:00Z</guid>
      <description>SAN DIEGO &amp;ndash; April 13, 2008 &amp;ndash; Amgen (NASDAQ:AMGN), today announced results from preclinical studies suggesting a significantly greater reduction in tumor growth when AMG 386, a recombinant Fc&#45;peptide fusion protein (peptibody) designed to bind angiopoietins 1 and 2, thereby inhibiting Tie2 dependent stimulation of endothelial cells, was combined with either of two vascular endothelial growth factor (VEGF) inhibitors&#8212;bevacizumab or motesanib diphosphate (AMG 706)&#8212;compared with either treatment alone (p less than 0.05). Angiopoietins, together with VEGFs, are key cytokines that regulate neovascularization. The results of preclinical studies that investigated the growth of human colon tumor cells in this combination were presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego.</description>
      <dc:subject>Press Releases, Pipeline News</dc:subject>
      <dc:date>2008-04-13T18:29:00+00:00</dc:date>
    </item>

    
    </channel>
</rss>